CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

@article{Scheen2008CB1RB,
  title={CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.},
  author={Andr{\'e} Scheen},
  journal={Journal of neuroendocrinology},
  year={2008},
  volume={20 Suppl 1},
  pages={139-46}
}
Rimonabant, the first selective CB(1) receptor antagonist in clinical use, has been extensively investigated in the Rimonabant in Obesity (RIO) programme, comprising four 1-2 year placebo-controlled randomised clinical trials recruiting more than 6600 overweight/obese patients with or without co-morbidities. Rimonabant 20 mg daily consistently reduced body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and increased HDL cholesterol… CONTINUE READING